A-share CRO Sector Index Surges 7.37% on Strong Earnings
On the morning of August 7, 2026, the A-share CRO sector index jumped 7.37%, leading all sector gains. Among 41 constituents, 15 stocks rose over 10%, including five limit-ups. WuXi AppTec reported first-half net profit of RMB 11.08 billion, up 29.43% year-on-year, with outstanding orders reaching RMB 66.43 billion, up 25.2%.
On the morning of August 7, the A-share CRO (contract research organization) sector index rose 7.37%, ranking first among all sector indices. Of the 41 constituent stocks in the sector, 15 gained more than 10%, with five stocks hitting the daily limit: Bide Pharmatech, GemPharmatech, Baihua Pharmaceutical, Apeloa Pharmaceutical, and Asymchem Laboratories. Another 17 stocks, including Biocytogen, Joinn Laboratories, Tigermed, and WuXi AppTec, rose more than 5%.
Earnings results were the primary driver behind the sector's rally.
WuXi AppTec's 2026 semi-annual report showed net profit attributable to shareholders of the listed company reached RMB 11.08 billion in the first half, up 29.43% year-on-year, marking the first time it surpassed RMB 10 billion in a half-year period. As of the end of June 2026, the company's backlog of orders for continuing operations stood at RMB 66.43 billion, up 25.2% from a year earlier.
The increase in order volumes at CRO companies is linked to the recovery in global demand for innovative drug R&D. Amid the continued rebound in global pharmaceutical investment and financing, demand for innovative drug R&D is showing a recovery trend. Growing market demand has driven both business volume and pricing upward, bringing new orders to CRO companies. Biocytogen, which mainly provides preclinical CRO services including gene-edited animal model generation, breeding and supply of innovative animal models, preclinical pharmacology and efficacy evaluation, and antibody drug discovery, saw its two major business lines develop in synergy during the reporting period, fueling sustained revenue growth.